Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, targets glycolate oxidase to reduce hepatic oxalate production, thereby reducing urinary oxalate excretion. This compound shows promise in addressing the underlying cause of progressive kidney failure in individuals with primary hyperoxaluria type 1 (PH1).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | Inquiry | $ 1,520.00 |
Description | Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, targets glycolate oxidase to reduce hepatic oxalate production, thereby reducing urinary oxalate excretion. This compound shows promise in addressing the underlying cause of progressive kidney failure in individuals with primary hyperoxaluria type 1 (PH1). |
In vitro | Lumasiran sodium is utilized in the study of Primary Hyperoxaluria Type 1 (PH1). It functions by silencing the gene responsible for glycolate oxidase production, subsequently reducing glycolate oxidase levels. This inhibition blocks oxalate synthesis, the harmful metabolite linked to PH1's clinical symptoms[1]. |
In vivo | Lumasiran sodium is a liver-targeted therapeutic agent administered subcutaneously, functioning through RNA interference (RNAi) [2]. |
Molecular Weight | N/A |
CAS No. | 1834612-06-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Lumasiran sodium 1834612-06-4 inhibitor inhibit